drugset / Trial / NCT06413498
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
RandomizedParallel-groupOpen-labelTreatment
Summary
The goal of this study (iMMagine-3) is to compare the study drug, anitocabtagene autoleucel to standard of care therapy (SOCT) in participants with relapsed/refractory multiple myeloma who have received 1 to 3 prior lines of therapy, including an anti-CD38 monoclonal antibody and an immunomodulatory drug. The primary objective of this study is to compare the efficacy of anitocabtagene autoleucel versus SOCT in participants with RRMM.
Timeline
- Start
- 2024-08-23
- Primary completion
- 2028-07
- Completion
- 2031-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anitocabtagene Autoleucel | Cell therapy | — | — |
| Comparator | Bortezomib | Small molecule | — | Intravenous |
| Comparator | Carfilzomib | Other / unclassified | — | Intravenous |
| Comparator | Daratumumab | Monoclonal antibody | — | Intravenous |
| Comparator | Dexamethasone | Small molecule | — | Oral |
| Comparator | Pomalidomide | Other / unclassified | — | Oral |
| Background | Cyclophosphamide | Other / unclassified | — | Intravenous |
| Background | Fludarabine | Small molecule | — | Intravenous |